Downstream Processing

Repligen talks product diversification through M&A and R&D

Exclusive interview from Biotech Week Boston

Balancing the up and downstream: Repligen CEO talks R&D and M&A

By Dan Stanton

Repligen’s customer GE Healthcare opted to make its latest Protein A ligand in-house, but CEO Tony Hunt remains confident in his firm’s long-term partnerships and diversified bioprocessing offering.

The VIA Thaw CB1000. Image: c/o GE Healthcare

GE launches cell therapy thawing tech

By Dan Stanton

GE Healthcare has launched a thawing technology for cell therapies it says removes the risks and inconsistencies of standard water baths.